Eligible for two schemes but these patients still can't get money for transplants
Eleven-year-old Sameer from Bihar ’s Muzaffarpur district is suffering from aplastic anaemia, and needs Rs 12 lakh for a bone marrow transplant. You would think that’s not a big hurdle since his mother’s name figures in the list of Ayushman Bharat beneficiaries but unfortunately his condition isn’t covered by the scheme.
The United States Public Health Service Flag Promotion ceremony for Rear Admiral (RADM) Richard W. Childs, promoted to RADM Upper Half O-8 in January 2020, is being webcast live on 3/27/2020 from Masur Auditorium. Richard Childs, MD serves as the Clinical Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). He was commissioned in the USPHS Commissioned Corps as a Lieutenant in 1995 when joined the NCI as an Oncology Fellow. Following fellowship training, he was appointed a tenure-track investigator in the Hematology Branch of the NHLBI where he continues to conduct r...
Bone Marrow Transplantation, Published online: 05 February 2020; doi:10.1038/s41409-020-0820-xComparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia
Bone Marrow Transplantation, Published online: 20 January 2020; doi:10.1038/s41409-020-0788-6Outcomes of conditioning with rabbit antithymocyte globulin and rituximab in haploidentical haematopoietic stem cell transplantation in patients with severe aplastic anaemia
CONCLUSIONS: Antibodies (Abs) against antigens on platelets (PLTs), including glycoprotein IV (CD36), can cause PLT refractoriness. Transfusing PLTs to patients with anti-CD36 is challenging because of the rarity of CD36-negative (CD36-) donors and the possibility of additional HLA Abs. We report a case of PLT refractoriness due to anti-CD36 and HLA Abs. A 21-year-old man (group O, D+) with assumed drug-induced aplastic anemia received multiple PLT transfusions and developed severe PLT refractoriness. He was found to have anti-CD36 as well as HLA class I Abs, with a CD36- phenotype on both PLTs and monocytes. He was diagno...
Bone Marrow Transplantation, Published online: 13 January 2020; doi:10.1038/s41409-020-0779-7Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia
Conclusion: Younger age, male predominance and higher consanguinity point toward genetic factors in AA etiology among the South Asian population. PMID: 31906834 [PubMed - in process]
Bone Marrow Transplantation, Published online: 16 December 2019; doi:10.1038/s41409-019-0773-0Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party
The treatment of choice for paediatric severe aplastic anaemia (SAA) is currently a human leucocyte antigen (HLA) matched sibling donor (MSD) transplant, with 2-5 year overall survival of 82-92% [1 –4]. Historically, immunosuppressive therapy (IST) was given to those who lacked a MSD but matched unrelated donor (MUD) transplant is now considered an alternative upfront treatment if a donor can be found quickly . This change partly reflects excellent results from alternative donor transplan ts but also lack of consistent long-term remission for those treated with IST alone [5–7].
Bone Marrow Transplantation, Published online: 29 October 2019; doi:10.1038/s41409-019-0736-5Unrelated cord blood transplantation for severe aplastic anemia using intensified immunoablative conditioning regimen leading to high engraftment and survival
Bone Marrow Transplantation, Published online: 25 September 2019; doi:10.1038/s41409-019-0680-4Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)